Emergence of SARS-CoV-2 Variants and Impact on IVD Testing - POCTRN
Center news
Emergence of SARS-CoV-2 Variants and Impact on IVD Testing
Learn more about COVID-19 Variants and their impact on the testing environment
Speakers:
Richard Creager, PhD
Co-Founder & Partner, NaviDx LLC
Eric Lai, PhD
Ex-SVP at Takeda Pharmaceutical and Head of R&D at Gen-Probe Diagnostics
This webinar took place on March 23, 2021:
RADx: Rapid Acceleration of Diagnostics
In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADx®) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.
In the News
NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests
The need for new test verification and regulatory support for innovative diagnostics
NIH-funded screening study builds case for frequent COVID-19 antigen testing
RADx partnerships speed new COVID testing
Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort
RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing (Login Required)
COVID-19 Testing: Three Breakthrough Solutions in the RADx Initiative
The National Strategy From the COVID-19 Response and Pandemic Preparedness